MSLN and neoplasm: As a potential target in the nanovaccine approach, we verified the expression of the tumor antigen MSLN in murine PDAC KPC cells and tumor samples from both PDAC patients and mice (Supplementary Figure S1), confirming that MSLN represents a suitable antigen target for vaccination.